financetom
Business
financetom
/
Business
/
Vontier's Fiscal Q1 Adjusted Earnings Increase, Sales Decline
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vontier's Fiscal Q1 Adjusted Earnings Increase, Sales Decline
May 25, 2025 11:22 PM

09:54 AM EDT, 05/01/2025 (MT Newswires) -- Vontier ( VNT ) reported fiscal Q1 adjusted earnings Thursday of $0.77 per diluted share, up from $0.74 a year earlier.

Analysts polled by FactSet expected $0.72.

Sales for the quarter ended March 28 were $741.1 million, down from $755.8 million a year earlier.

Analysts surveyed by FactSet expected $720.9 million.

The company said it expects fiscal Q2 adjusted EPS of $0.70 to $0.75 and sales of $725 million to $745 million. Analysts polled by FactSet expect $0.72 in adjusted EPS on sales of $729.8 million.

For fiscal 2025, Vontier ( VNT ) reiterated its outlook of $3.00 to $3.15 in adjusted EPS and $2.97 billion to $3.05 billion in sales. Analysts polled by FactSet expect $3.08 in adjusted EPS on sales of $3.01 billion.

Shares of Vontier ( VNT ) were up more than 4% in recent trading Thursday.

Price: 33.13, Change: +1.32, Percent Change: +4.15

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BioAtla's Ozuriftamab Vedotin Receives FDA Fast-Track Designation; Shares Rise
BioAtla's Ozuriftamab Vedotin Receives FDA Fast-Track Designation; Shares Rise
Jul 23, 2024
09:38 AM EDT, 07/23/2024 (MT Newswires) -- BioAtla ( BCAB ) said Tuesday that the US Food and Drug Administration has granted fast-track designation to ozuriftamab vedotin, the company's drug candidate to treat patients with squamous cell carcinoma of the head and neck. The designation applies to drugs that are intended to treat a serious or life-threatening disease or condition,...
FactSet Names Helen Shan CFO, Goran Skoko Chief Revenue Officer
FactSet Names Helen Shan CFO, Goran Skoko Chief Revenue Officer
Jul 23, 2024
09:44 AM EDT, 07/23/2024 (MT Newswires) -- FactSet Research Systems ( FDS ) said Tuesday that Helen Shan has been named chief financial officer, effective immediately, succeeding Linda Huber, who is leaving the company. Shan was previously chief revenue officer and served as CFO of FactSet from 2018 to 2021, the company said. Goran Skoko was named to succeed Shan...
Pentair Navigates Economic Headwinds, Posts Q2 Earnings Beat, Updates Outlook & More
Pentair Navigates Economic Headwinds, Posts Q2 Earnings Beat, Updates Outlook & More
Jul 23, 2024
Pentair plc ( PNR ) reported a second-quarter 2024 net sales rose 2% Y/Y to $1.099 billion, marginally beating the consensus of $1.095 billion. Excluding currency translation, acquisitions and divestitures, core sales grew 2% in the second quarter. The gross margin expanded to 39.8% from 36.9% a year ago. Operating income rose 19% YoY to $248 million, and the operating margin expanded 330 basis points Y/Y to 22.6%. On an adjusted basis, the operating margin increased by...
Anixa Partner Gets FDA Nod for Second CAR-T Treatment to Ovarian Cancer Patient
Anixa Partner Gets FDA Nod for Second CAR-T Treatment to Ovarian Cancer Patient
Jul 23, 2024
09:42 AM EDT, 07/23/2024 (MT Newswires) -- Anixa Biosciences ( ANIX ) said Tuesday that the US Food and Drug Administration has approved its partner Moffitt Cancer Center's individual patient Investigational New Drug application, allowing a second dose of its CAR-T therapy for a patient indicating clinical activity to the initial treatment. The company said the approval follows biopsy results...
Copyright 2023-2026 - www.financetom.com All Rights Reserved